ValiRx plc

Default features description for sign up page.

Careers

Collaborative Pipeline

Board & Management Team

Privacy Policy

How we work

Strategy & Vision

Updates

Analyst Research

AIM Rule 26

Share Price Information

Reports, AGMs & Presentations

Regulatory News

Webinars

Partnering & Useful Links

Therapeutic Areas

Inaphaea Biolabs

Evaluation Pipeline

Our Pipeline

Home

Contact Us

DM Sans

Very happy to announce progress on the current patents for Cytolytix. Now we have notice of allowance for the nanoparticle formulation we'll be completing formalities like filing the translations into French and German, as required by the EU patent office. We will then pay the required fee after which the patent should grant within a couple of months.

In the case of the second patent, an accelerated examination request is typically completed within 3 months followed by the same process outlined above.

For those not familiar with the patent process, it's useful to note that patent coverage begins from the priority date in the earliest patent submission, NOT the grant date so once we know claims will be granted, we know we have coverage. We are building on this strong base with new filings anticipated to cover novel aspects of the technology which we can then disclose publicly, an important part of our commercialisation strategy as we promote the program at various conferences and partnering meetings.